Publication
Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerHead and Neck Squamous Cell Carcinomacivic_curation1.00
- drugCetuximabcivic_curation1.00
- drugDocetaxelcivic_curation1.00
- geneAREGcivic_curation1.00
- geneEGFRcivic_curation1.00
- variantAREG Expressioncivic_curation1.00
- variantEGFR Overexpressioncivic_curation1.00
- variantEGFR VIIIcivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 21653686
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| AREG Expression2 | ||||||||
| Unspecified therapy | Head and Neck Squamous Cell Carcinoma | Predictive | B | Supports Resistance | 3 | rejected | EID84747 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 45% of cases expressed high level of AREG. High AREG expression in tum… (full text at CIViC) PMID 21653686 · Tinhofer et al., 2011 · Open in CIViC | civic |
| Cetuximab + DocetaxelCombination | Head and Neck Squamous Cell Carcinoma | Predictive | B | Supports Resistance | 2 | accepted | EID84647 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 45% of cases expressed high level of AREG. High AREG expression in tum… (full text at CIViC) PMID 21653686 · Tinhofer et al., 2011 · Open in CIViC | civic |
| EGFR Overexpression1 | ||||||||
| Cetuximab + DocetaxelCombination | Head and Neck Squamous Cell Carcinoma | Predictive | B | Does Not Support Sensitivity Response | 3 | accepted | EID84947 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 73 % of cases expressed high level of EGFR. EGFR expression had no imp… (full text at CIViC) PMID 21653686 · Tinhofer et al., 2011 · Open in CIViC | civic |
| EGFR VIII1 | ||||||||
| Cetuximab + DocetaxelCombination | Head and Neck Squamous Cell Carcinoma | Predictive | B | Supports Resistance | 2 | accepted | EID84847 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR, and AREG expression by IHC. 17% of cases expressed high levels of EGFRvIII. High vIII expression wa… (full text at CIViC) PMID 21653686 · Tinhofer et al., 2011 · Open in CIViC | civic |